

Latanoprost ELISA Kit

Item No. 516811

www.caymanchem.com

Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd · Ann Arbor, MI · USA

TABLE OF CONTENTS

GENERAL INFORMATION 3 Materials Supplied

4 Safey Data

4 Precautions

5 If You Have Problems

5 Storage and Stability

5 Materials Needed but Not Supplied

INTRODUCTION 6 Background

7 About This Assay

8 Description of AChE Competitive ELISAs

9 Biochemistry of Acetylcholinesterase

11 Definition of Key Terms

PRE-ASSAY PREPARATION 12 Buffer Preparation

13 Sample Preparation

ASSAY PROTOCOL 14 Preparation of Assay-Specific Reagents

19 Plate Set Up

20 Performing the Assay

ANALYSIS 23 Calculations

24 Performance Characteristics

RESOURCES 32 Troubleshooting

33 References

34 Plate Template

35 Notes

35 Warranty and Limitation of Remedy

GENERAL INFORMATION

Materials Supplied

Item Number	ltem	96 wells Quantity/Size	480 wells Quantity/Size
416812	Latanoprost ELISA Antiserum	1 vial/100 dtn	1 vial/500 dtn
416810	Latanoprost AChE Tracer	1 vial/100 dtn	1 vial/500 dtn
416814	Latanoprost (free acid) ELISA Standard	1 vial	1 vial
416815	Latanoprost ELISA Standard	1 vial	1 vial
400060	ELISA Buffer Concentrate (10X)	2 vials/10 ml	4 vials/10 ml
400062	Wash Buffer Concentrate (400X)	1 vial/5 ml	1 vial/12.5 ml
400035	Polysorbate 20	1 vial/3 ml	1 vial/3 ml
400004/400006	Mouse Anti-Rabbit IgG Coated Plate	1 plate	5 plates
400012	96-Well Cover Sheet	1 cover	5 covers
400050	Ellman's Reagent	3 vials/100 dtn	6 vials/250 dtn
400040	ELISA Tracer Dye	1 vial	1 vial
400042	ELISA Antiserum Dye	1 vial	1 vial

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user <u>must</u> review the <u>complete</u> Safety Data Sheet, which has been sent *via* email to your institution.

Precautions

Please read these instructions carefully before beginning this assay.

The reagents in this kit have been tested and formulated to work exclusively with Cayman Chemical's Latanoprost ELISA Kit. This kit may not perform as described if any reagent or procedure is replaced or modified.

When compared to quantification by LC/MS or GC/MS, it is not uncommon for immunoassays to report higher analyte concentrations. While LC/MS or GC/MS analyses typically measure only a single compound, antibodies used in immunoassays sometimes recognize not only the target molecule, but also structurally related molecules, including biologically relevant metabolites. In many cases, measurement of both the parent molecule and metabolites is more representative of the overall biological response than is the measurement of a short-lived parent molecule. It is the responsibility of the researcher to understand the limits of both assay systems and to interpret their data accordingly.

If You Have Problems

Technical Service Contact Information

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888

Email: techserv@caymanchem.com

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Storage and Stability

This kit will perform as specified if stored as directed at -20°C and used before the expiration date indicated on the outside of the box.

Materials Needed But Not Supplied

- A plate reader capable of measuring absorbance between 405-420 nm.
- 2. Adjustable pipettes and a repeating pipettor.
- 3. A source of 'UltraPure' water. Water used to prepare all ELISA reagents and buffers must be deionized and free of trace organic contaminants ('UltraPure'). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for ELISA. NOTE: UltraPure water is available for purchase from Cayman (Item No. 400000).
- 4. Materials used for Sample Preparation (see page 13).

INTRODUCTION

Background

Latanoprost is 13,14-dihydro-17-phenyl-18,19,20-trinor Prostaglandin $F_{2\alpha}$ (PGF $_{2\alpha}$) isopropyl ester, an F-series PG analog which has been approved for use as an ocular hypotensive drug. ¹⁻³ PG esters and other similar derivatives act as prodrugs which are converted to the active free acid form by an esterase/amidase activity in ocular tissues. The free acid form of latanoprost (latanoprost free acid (Lat-FA); PhXA 85) is 200 times more potent than the isopropyl ester as an FP receptor ligand tested using the recombinant human FP receptor. ² Although the exact mechanism of the intraocular hypotensive effect of PGs is unknown, it correlates very closely with the FP receptor ligand binding affinity of FP receptor agonists. ⁴

The pharmacokinetics of latanoprost have been studied in monkeys,⁵ but are still uncertain in some respects. Within five minutes after application of a 1-3 μ g dose of latanoprost to the eye of the Cynomolgus monkey, plasma levels of the free acid metabolite have been measured in the range of 500 pg/ml. The concentration and the ester/free acid distribution of latanoprost in the aqueous humor at the same time point is not known. Once the free acid of latanoprost reaches the blood compartment it is further metabolized, mostly by β -oxidation of the α -chain and excreted within a few hours.⁵

About This Assay

Cayman's Latanoprost ELISA Kit is a sensitive detection method for measuring the free acid form of latanoprost. The kit also detects the isopropyl ester form of latanoprost, but with less sensitivity. The assay is most appropriate for use when only one of the two forms is present. Samples containing mixtures of both the isopropyl ester and free acid should be purified and the two compounds separated prior to ELISA analysis. The assay has a range from 3.9-500 pg/ml and a sensitivity (80% B/B $_0$) of approximately 15.5 pg/ml for latanoprost (free acid) with a range from 15.6-2,000 pg/ml and a sensitivity (80% B/B $_0$) of approximately 43 pg/ml for the isopropyl ester.


INTRODUCTION


Description of AChE Competitive ELISAs^{6,7}

This assay is based on the competition between latanoprost and a latanoprost-acetylcholinesterase (AChE) conjugate (latanoprost tracer) for a limited number of latanoprost-specific rabbit antiserum binding sites. Because the concentration of the latanoprost tracer is held constant while the concentration of latanoprost varies, the amount of latanoprost tracer that is able to bind to the rabbit antiserum will be inversely proportional to the concentration of latanoprost in the well. This rabbit antiserum-latanoprost (either free or tracer) complex binds to the mouse monoclonal anti-rabbit IgG that has been previously attached to the well. The plate is washed to remove any unbound reagents and then Ellman's Reagent (which contains the substrate to AChE) is added to the well. The product of this enzymatic reaction has a distinct yellow color and absorbs strongly at 412 nm. The intensity of this color, determined spectrophotometrically, is proportional to the amount of latanoprost tracer bound to the well, which is inversely proportional to the amount of free latanoprost present in the well during the incubation; or

Absorbance ∞ [Bound Latanoprost Tracer] ∞ 1/[Latanoprost]

A schematic of this process is shown below in Figure 1.





Biochemistry of Acetylcholinesterase

The electric organ of the electric eel, *E. electricus*, contains an avid AChE capable of massive catalytic turnover during the generation of its electrochemical discharges. The electric eel AChE has a clover leaf-shaped tertiary structure consisting of a triad of tetramers attached to a collagen-like structural fibril. This stable enzyme is capable of high turnover (64,000 s⁻¹) for the hydrolysis of acetylthiocholine.

A molecule of the analyte covalently attached to a molecule of AChE serves as the tracer in AChE enzyme immunoassays. Quantification of the tracer is achieved by measuring its AChE activity with Ellman's Reagent. This reagent consists of acetylthiocholine and 5,5'-dithio-bis-(2-nitrobenzoic acid). Hydrolysis of acetylthiocholine by AChE produces thiocholine (see Figure 2, on page 10). The non-enzymatic reaction of thiocholine with 5,5'-dithio-bis-(2-nitrobenzoic acid) produces 5-thio-2-nitrobenzoic acid, which has a strong absorbance at 412 nm (ϵ = 13,600).

AChE has several advantages over other enzymes commonly used for enzyme immunoassays. Unlike horseradish peroxidase, AChE does not self-inactivate during turnover. This property of AChE also allows redevelopment of the assay if it is accidentally splashed or spilled. In addition, the enzyme is highly stable under the assay conditions, has a wide pH range (pH 5-10), and is not inhibited by common buffer salts or preservatives. Since AChE is stable during the development step, it is unnecessary to use a 'stop' reagent, and the plate may be read whenever it is convenient.




Figure 2. Reaction catalyzed by acetylcholinesterase

INTRODUCTION

Definition of Key Terms

Blank: background absorbance caused by Ellman's Reagent. The blank absorbance should be subtracted from the absorbance readings of <u>all</u> the other wells, including NSB wells.

Total Activity: total enzymatic activity of the AChE-linked tracer. This is analogous to the specific activity of a radioactive tracer.

NSB (Non-Specific Binding): non-immunological binding of the tracer to the well. Even in the absence of specific antibody a very small amount of tracer still binds to the well; the NSB is a measure of this low binding. Do not forget to subtract the Blank absorbance values.

 ${\bf B_0}$ (Maximum Binding): maximum amount of the tracer that the antibody can bind in the absence of free analyte.

 $\rm \%B/B_0$ ($\rm \%Bound/Maximum\ Bound$): ratio of the absorbance of a particular sample or standard well to that of the maximum binding ($\rm B_0$) well.

Standard Curve: a plot of the $\%B/B_0$ values *versus* concentration of a series of wells containing various known amounts of analyte.

Dtn: determination, where one dtn is the amount of reagent used per well.

Cross Reactivity: numerical representation of the relative reactivity of this assay towards structurally related molecules as compared to the primary analyte of interest. Biomolecules that possess similar epitopes to the analyte can compete with the assay tracer for binding to the primary antibody. Substances that are superior to the analyte in displacing the tracer result in a cross reactivity that is greater than 100%. Substances that are inferior to the primary analyte in displacing the tracer result in a cross reactivity that is less than 100%. Cross reactivity is calculated by comparing the mid-point (50% B/B_0) value of the tested molecule to the mid-point (50% B/B_0) value of the primary analyte when each is measured in assay buffer using the following formula:

% Cross Reactivity =
$$\left[\frac{50\% \text{ B/B}_0 \text{ value for the primary analyte}}{50\% \text{ B/B}_0 \text{ value for the potential cross reactant}} \right] \times 100\%$$

PRE-ASSAY PREPARATION

NOTE: Water used to prepare all ELISA reagents and buffers must be deionized and free of trace organic contaminants ('UltraPure'). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for ELISA. UltraPure water may be purchased from Cayman (Item No. 400000).

Buffer Preparation

Store all diluted buffers at 4°C; they will be stable for about two months.

1. ELISA Buffer Preparation

Dilute the contents of one vial of ELISA Buffer Concentrate (10X) (Item No. 400060) with 90 ml of UltraPure water. Be certain to rinse the vial to remove any salts that may have precipitated. NOTE: It is normal for the concentrated buffer to contain crystalline salts after thawing. These will completely dissolve upon dilution with water.

2. Wash Buffer Preparation

5 ml vial Wash Buffer Concentrate (400X) (96-well kit; Item No. 400062): Dilute to a total volume of 2 liters with UltraPure water and add 1 ml of Polysorbate 20 (Item No. 400035).

OR

12.5 ml vial Wash Buffer Concentrate (400X) (480-well kit; Item No. 400062): Dilute to a total volume of 5 liters with UltraPure water and add 2.5 ml of Polysorbate 20 (Item No. 400035).

Smaller volumes of Wash Buffer can be prepared by diluting the Wash Buffer Concentrate 1:400 and adding Polysorbate 20 (0.5 ml/liter of Wash Buffer).

NOTE: Polysorbate 20 is a viscous liquid and cannot be measured by a regular pipette. A positive displacement pipette or a syringe should be used to deliver small quantities accurately.

Sample Preparation

Aqueous humor and human tear samples may be diluted with ELISA Buffer and added directly to the assay well. Plasma, serum, whole blood, as well as other heterogeneous mixtures such as CSF often contain contaminants which can interfere in the assay. It is best to check for interference before embarking on a large number of sample measurements. To test for interference, dilute one or two test samples to obtain at least two different dilutions of each sample between 20-250 pg/ml for latanoprost (free acid) or 50-1,000 pg/ml for latanoprost. If the two different dilutions of the sample show good correlation (differ by 20% or less) in the final calculated latanoprost concentration, purification is not required. If you do not see good correlation of the different dilutions, purification is advised. Purification of latanoprost prior to ELISA analysis has not been validated. References for prostaglandin purification are provided on page 33.8,9

General Precautions

- All samples must be free of organic solvents prior to assay.
- Samples should be assayed immediately after collection; samples that cannot be assayed immediately should be stored at -80°C.
- Samples of rabbit origin may contain antibodies which interfere with the assay by binding to the mouse anti-rabbit plate. We recommend that all rabbit samples be purified prior to use in this assay.

Plasma

Plasma samples should be collected in vacutainers containing sodium, heparin, or EDTA. Vacutainers can also be supplemented with indomethacin to give a final concentration of at least 10 μ M. Indomethacin will prevent *ex vivo* formation of eicosanoids, which have the potential to interfere with this assay (although most eicosanoids do not appear to exhibit any cross reactivity (see page 31)).

ASSAY PROTOCOL

Preparation of Assay-Specific Reagents

This assay can be used for the quantification of either latanoprost free acid or latanoprost isopropyl ester. Because the assay detects both compounds, it is suited to samples containing only one of the two compounds. Samples containing a mixture of the isopropyl ester and free acid should be purified and the two compounds separated prior to ELISA analysis


Protocols for preparing both a latanoprost (free acid) standard curve and a latanoprost isopropyl ester standard curve are shown on pages 15-16. Prepare the standard curve that is most relavent for your samples.

Latanoprost (free-acid) ELISA Standard

Equilibrate a pipette tip in ethanol by repeatedly filling and expelling the tip with ethanol several times. Using the equilibrated pipette tip, transfer 100 μl of the Latanoprost (free-acid) ELISA Standard (Item No. 416814) into a clean test tube, then dilute with 900 μl UltraPure water. The concentration of this solution (the bulk standard) will be 5 ng/ml. Extra standard has been provided in the event additional standard curves are required.

NOTE: If assaying culture medium samples that have not been diluted with ELISA Buffer, culture medium should be used in place of ELISA Buffer for dilution of the standard curve.

To prepare the standard for use in ELISA: Obtain eight clean test tubes and number them #1 through #8. Aliquot 900 μ I ELISA Buffer to tube #1 and 500 μ I ELISA Buffer to tubes #2-8. Transfer 100 μ I of the bulk standard (5 ng/mI) to tube #1 and mix thoroughly. Serially dilute the standard by removing 500 μ I from tube #1 and placing in tube #2; mix thoroughly. Next, remove 500 μ I from tube #2 and place it into tube #3; mix thoroughly. Repeat this process for tubes #4-8. These diluted standards should not be stored for more than 24 hours.



15

Figure 3. Preparation of the Latanoprost (free-acid) standards

Latanoprost ELISA Standard

Equilibrate a pipette tip in ethanol by repeatedly filling and expelling the tip with ethanol several times. Using the equilibrated pipette tip, transfer 100 μ l of the Latanoprost ELISA Standard (Item No. 416815) into a clean test tube, then dilute with 900 μ l UltraPure water. The concentration of this solution (the bulk standard) will be 20 ng/ml.

NOTE: If assaying culture medium samples that have not been diluted with ELISA Buffer, culture medium should be used in place of ELISA Buffer for dilution of the standard curve.

To prepare the standard for use in ELISA: Obtain eight clean test tubes and number them #1 through #8. Aliquot 900 μ I ELISA Buffer to tube #1 and 500 μ I ELISA Buffer to tubes #2-8. Transfer 100 μ I of the bulk standard (20 ng/mI) to tube #1 and mix thoroughly. Serially dilute the standard by removing 500 μ I from tube #1 and placing in tube #2; mix thoroughly. Next, remove 500 μ I from tube #2 and place it into tube #3; mix thoroughly. Repeat this process for tubes #4-8. These diluted standards should not be stored for more than 24 hours.




Figure 4. Preparation of the Latanoprost standards

Latanoprost AChE Tracer

Reconstitute the Latanoprost AChE Tracer as follows:

100 dtn Latanoprost AChE Tracer (96-well kit; Item No. 416810): Reconstitute with 6 ml ELISA Buffer.

OR

500 dtn Latanoprost AChE Tracer (480-well kit; Item No. 416810): Reconstitute with 30 ml ELISA Buffer.

Store the reconstituted Latanoprost AChE Tracer at 4°C (do not freeze!) and use within four weeks. A 20% surplus of tracer has been included to account for any incidental losses.

Tracer Dye Instructions (optional)

This dye may be added to the tracer, if desired, to aid in visualization of tracer-containing wells. Add the dye to the reconstituted tracer at a final dilution of 1:100 (add 60 μ l of dye to 6 ml tracer or add 300 μ l of dye to 30 ml of tracer). NOTE: Do not store tracer with dye for more than 24 hours.

16 ASSAY PROTOCOL

Latanoprost ELISA Antiserum

Reconstitute the Latanoprost ELISA Antiserum as follows:

100 dtn Latanoprost ELISA Antiserum (96-well kit; Item No. 416812): Reconstitute with 6 ml ELISA Buffer.

OR

500 dtn Latanoprost ELISA Antiserum (480-well kit; Item No. 416812): Reconstitute with 30 ml ELISA Buffer.

Store the reconstituted Latanoprost ELISA Antiserum at 4°C. It will be stable for at least four weeks. A 20% surplus of antiserum has been included to account for any incidental losses.

Antiserum Dye Instructions (optional)


This dye may be added to the antiserum, if desired, to aid in visualization of antiserum-containing wells. Add the dye to the reconstituted antiserum at a final dilution of 1:100 (add 60 μ l of dye to 6 ml antiserum or add 300 μ l of dye to 30 ml of antiserum). NOTE: Do not store antiserum with dye for more than 24 hours.

Plate Set Up

The 96-well plate(s) included with this kit is supplied ready to use. It is not necessary to rinse the plate(s) prior to adding the reagents. NOTE: If you do not need to use all the strips at once, place the unused strips back in the plate packet and store at 4°C. Be sure the packet is sealed with the desiccant inside.

Each plate or set of strips must contain a minimum of two blanks (Blk), two non-specific binding wells (NSB), two maximum binding wells (B₀), and an eight point standard curve run in duplicate. NOTE: Each assay must contain this minimum configuration in order to ensure accurate and reproducible results. Each sample should be assayed at two dilutions and each dilution should be assayed in duplicate. For statistical purposes, we recommend assaying samples in triplicate.

A suggested plate format is shown in Figure 5, below. The user may vary the location and type of wells present as necessary for each particular experiment. The plate format provided below has been designed to allow for easy data analysis using a convenient spreadsheet offered by Cayman (see page 23, for more details). We suggest you record the contents of each well on the template sheet provided (see page 34).



Blk - Blank TA - Total Activity NSB - Non-Specific Binding B₀ - Maximum Binding S1-S8 - Standards 1-8 1-24 - Samples

Figure 5. Sample plate format

Performing the Assay

Pipetting Hints

- Use different tips to pipette each reagent.
- Before pipetting each reagent, equilibrate the pipette tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).
- Do not expose the pipette tip to the reagent(s) already in the well.

Addition of the Reagents

1. ELISA Buffer

Add 100 μ l ELISA Buffer to NSB wells. Add 50 μ l ELISA Buffer to B $_0$ wells. If culture medium was used to dilute the standard curve, substitute 50 μ l of culture medium for ELISA Buffer in the NSB and B $_0$ wells (i.e., add 50 μ l culture medium to NSB and B $_0$ wells and 50 μ l ELISA Buffer to NSB wells).

2. Latanoprost or Latanoprost (free acid) ELISA Standard

Add 50 μ l from tube #8 to both of the lowest standard wells (S8). Add 50 μ l from tube #7 to each of the next two standard wells (S7). Continue with this procedure until all the standards are aliquoted. The same pipette tip should be used to aliquot all the standards. Before pipetting each standard, be sure to equilibrate the pipette tip in that standard.

3. Samples

Add 50 μ l of sample per well. Each sample should be assayed at a minimum of two dilutions. Each dilution should be assayed in duplicate (triplicate recommended).

4. Latanoprost AChE Tracer

Add 50 μ I to each well except the TA and the Blk wells.

5. Latanoprost ELISA Antiserum

Add 50 μ l to each well except the TA, the NSB, and the Blk wells.

Well	ELISA Buffer	Standard/Sample	Tracer	Antiserum
Blk	-	-	-	-
TA	-	-	5 μl (at devl. step)	-
NSB	100 μΙ	-	50 μΙ	-
B ₀	50 μΙ	-	50 μΙ	50 μΙ
Std/Sample	-	50 μΙ	50 μΙ	50 μΙ

Table 1. Pipetting summary

Incubation of the Plate

Cover each plate with plastic film (Item No. 400012) and incubate for two hours at room temperature on an orbital shaker.

Development of the Plate

1. Reconstitute Ellman's Reagent immediately before use (20 ml of reagent is sufficient to develop 100 wells):

100 dtn vial Ellman's Reagent (96-well kit; Item No. 400050): Reconstitute with 20 ml of UltraPure water.

OR

250 dtn vial Ellman's Reagent (480-well kit; Item No. 400050): Reconstitute with 50 ml of UltraPure water.

NOTE: Reconstituted Ellman's Reagent is unstable and should be used the same day it is prepared; protect the Ellman's Reagent from light when not in use. Extra vials of the reagent have been provided should a plate need to be re-developed or multiple assays be run on different days.

- 2. Empty the wells and rinse five times with Wash Buffer.
- 3. Add 200 µl of Ellman's Reagent to each well
- 4. Add 5 μ l of tracer to the TA wells.
- Cover the plate with plastic film. Optimum development is obtained by using an <u>orbital shaker</u> equipped with a large, flat cover to allow the plate(s) to develop in the dark. This assay typically develops (i.e., B₀ wells ≥0.3 A.U. (blank subtracted)) in 60-90 minutes.

Reading the Plate

- Wipe the bottom of the plate with a clean tissue to remove fingerprints, dirt, etc.
- 2. Remove the plate cover being careful to keep Ellman's Reagent from splashing on the cover. NOTE: Any loss of Ellman's Reagent will affect the absorbance readings. If Ellman's Reagent is present on the cover, use a pipette to transfer the Ellman's Reagent into the well. If too much Ellman's Reagent has splashed on the cover to easily redistribute back into the wells, wash the plate three times with wash buffer and repeat the development with fresh Ellman's Reagent.
- 3. Read the plate at a wavelength between 405 and 420 nm. The absorbance may be checked periodically until the $\rm B_0$ wells have reached a minimum of 0.3 A.U. (blank subtracted). The plate should be read when the absorbance of the $\rm B_0$ wells in the range of 0.3-1.0 A.U. (blank subtracted). If the absorbance of the wells exceeds 2.0, wash the plate, add fresh Ellman's Reagent and let it develop again.

ANALYSIS

Many plate readers come with data reduction software that plots data automatically. Alternatively a spreadsheet program can be used. The data should be plotted as either $\%B/B_0$ versus log concentration using a four-parameter logistic fit or as logit B/B_0 versus log concentration using a linear fit. NOTE: Cayman Chemical has a computer spreadsheet available for data analysis. Please contact Technical Service or visit our website (www.caymanchem.com/analysis/elisa) to obtain a free copy of this convenient data analysis tool.

Calculations

Preparation of the Data

The following procedure is recommended for preparation of the data prior to graphical analysis.

NOTE: If the plate reader has not subtracted the absorbance readings of the blank wells from the absorbance readings of the rest of the plate, be sure to do that now.

- 1. Average the absorbance readings from the NSB wells.
- 2. Average the absorbance readings from the B_0 wells.
- Subtract the NSB average from the B₀ average. This is the corrected B₀ or corrected maximum binding.
- 4. Calculate the B/B_0 (Sample or Standard Bound/Maximum Bound) for the remaining wells. To do this, subtract the average NSB absorbance from the S1 absorbance and divide by the corrected B_0 (from Step 3). Repeat for S2-S8 and all sample wells. (To obtain $\%B/B_0$ for a logistic four-parameter fit, multiply these values by 100.)

NOTE: The TA values are not used in the standard curve calculations. Rather, they are used as a diagnostic tool; the corrected B_0 divided by the actual TA (10X measured absorbance) will give the %Bound. This value should closely approximate the %Bound that can be calculated from the Sample Data (see pages 25 and 28). Erratic absorbance values and a low (or no) %Bound could indicate the presence of organic solvents in the buffer or other technical problems (see page 32 for Troubleshooting).

Plot the Standard Curve

Plot $\%B/B_0$ for standards S1-S8 *versus* latanoprost concentration using linear (y) and log (x) axes and perform a 4-parameter logistic fit.

Alternative Plot - The data can also be lineraized using a logit transformation. The equation for this conversion is shown below. NOTE: Do not use $\%B/B_0$ in this calculation.

$$logit (B/B_0) = ln [B/B_0/(1 - B/B_0)]$$

Plot the data as logit (B/B_0) versus log concentrations and perform a linear regression fit.

Determine the Sample Concentration

Calculate the B/B_0 (or $\%B/B_0$) value for each sample. Determine the concentration of each sample by identifying the $\%B/B_0$ on the standard curve and reading the corresponding values on the x-axis. *NOTE: Remember to account for any concentration of the sample prior to the addition to the well.* Samples with $\%B/B_0$ values greater than 80% or less than 20% should be re-assayed as they generally fall out of the linear range of the standard curve. A 20% or greater disparity between the apparent concentration of two different dilutions of the same sample indicates interference which could be eliminated by purification.

Performance Characteristics

Performance characteristics using the latanoprost (free acid) standard are shown on pages 25 and 26. Similar information for the latanoprost standard is found on pages 28 and 29.

Sample Data for Latanoprost (free acid)

The standard curve presented here is an example of the data typically produced with this kit; however, your results will not be identical to these. You <u>must</u> run a new standard curve. Do not use the data below to determine the value of your samples. Your results could differ substantially.

	Raw D	ata	Average Corrected	
Total Activity	0.372	0.402	0.387	0.387
NSB	0.000	0.000	0.000	
B_0	0.308	0.309		
	0.299	0.329	0.311	0.311

Dose (pg/ml)	Raw	Data	Corr	ected	%В	/B ₀
500	0.043	0.040	0.043	0.040	13.8	12.9
250	0.077	0.081	0.077	0.081	24.8	26.0
125	0.109	0.109	0.109	0.109	35.0	35.0
62.5	0.147	0.150	0.147	0.150	47.3	48.2
31.3	0.190	0.196	0.190	0.196	61.1	63.0
15.6	0.232	0.234	0.232	0.234	74.6	75.2
7.8	0.270	0.264	0.270	0.264	86.8	84.9
3.9	0.304	0.293	0.304	0.293	97.7	94.2

Table 2. Typical results




Figure 6. Typical Latanoprost (free acid) standard curve

Precision:

The intra- and inter-assay CVs have been determined at multiple points. These data are summarized in the graph on page 26 and in the table below.

Dose (pg/ml)	%CV* Intra-assay variation	%CV* Inter-assay variation
125	7.6	10.9
90	8.5	12.4
50	10.8	13.3
20	15.3	17.9
10	†	t

Table 3. Intra- and inter-assay variation for Latanoprost (free acid)

†Outside of the recommended usable range of the assay.

^{*%}CV represents the variation in concentration (not absorbance) of as determined using a reference standard curve.

Sample Data for Latanoprost

The standard curve presented here is an example of the data typically produced with this kit; however, your results will not be identical to these. You <u>must</u> run a new standard curve. Do not use the data below to determine the value of your samples. Your results could differ substantially.

	Raw D	ata	Average Corrected	
Total Activity	0.819	0.841	0.830	
NSB	0.003	0.000	0.002	
B ₀	0.435	0.438		
	0.442	0.420	0.434	0.432

Dose (pg/ml)	Raw	Data	Corr	ected	%В	/B ₀
2,000	0.040	0.045	0.038	0.043	8.9	10.1
1,000	0.099	0.091	0.097	0.089	22.6	20.7
500	0.144	0.150	0.142	0.148	33.0	34.6
250	0.209	0.206	0.207	0.204	48.0	47.3
125	0.287	0.266	0.285	0.264	66.0	61.2
62.5	0.313	0.317	0.311	0.315	72.1	73.0
31.3	0.361	0.342	0.359	0.340	83.2	78.8
15.6	0.409	0.377	0.407	0.375	94.3	86.9

Table 4. Typical results




Figure 7. Typical Latanoprost standard curve

Precision:

The intra- and inter-assay CVs have been determined at multiple points. These data are summarized in the graph on page 29 and in the table below.

Dose (pg/ml)	Pose (pg/ml) %CV* %CV* Intra-assay variation Inter-assay va	
1,000	6.8	12.7
700	10.4	12.5
400	12.8	13.8
100	15.9	22.3
50	20	†

Table 5. Intra- and inter-assay variation for Latanoprost

†Outside of the recommended usable range of the assay.

Cross Reactivity:

Compound	Cross Reactivity	Compound	Cross Reactivity
Latanoprost (free acid)	100%	tetranor-PGEM	<0.01%
5-trans Latanoprost	25.4%	tetranor-PGFM	<0.01%
Latanoprost	25%	Prostaglandin D ₂	<0.01%
17-phenyl Prostaglandin F _{2α}	3%	Prostaglandin E ₂	<0.01%
17-phenyl Prostaglandin $F_{2\alpha}$ ethyl amide	0.70%	Prostaglandin E ₂ Ethanolamide	<0.01%
15-epi Latanoprost	0.16%	6-keto Prostaglandin F _{1α}	<0.01%
15-keto Latanoprost	0.10%	Prostaglandin F _{2α}	<0.01%
Fluprostenol	<0.01%	Prostaglandin F _{2α} Ethanolamide	<0.01%
Fluprostenol isopropyl ester	<0.01%	5-trans Prostaglandin F _{2α}	<0.01%
2,3-dinor Fluprostenol	<0.01%	Thromboxane B ₂	<0.01%
9-keto Fluprostenol	<0.01%	Unoprostone	<0.01%
11-keto Fluprostenol	<0.01%	Unoprostone isopropyl ester	<0.01%

Table 6. Cross Reactivity of the Latanoprost ELISA

^{*%}CV represents the variation in concentration (not absorbance) of as determined using a reference standard curve.

RESOURCES

Troubleshooting

Problem	Possible Causes	Recommended Solutions
Erratic values; dispersion of duplicates	A. Trace organic contaminants in the water source B. Poor pipetting/technique	A. Replace activated carbon filter or change source of UltraPure water
High NSB (>10% of B ₀)	A. Poor washing B. Exposure of NSB wells to specific antibody	A. Re-wash plate and redevelop
Very low B ₀	A. Trace organic contaminants in the water source B. Plate requires additional development time C. Dilution error in preparing reagents	Replace activated carbon filter or change source of UltraPure water Return plate to shaker and re-read later
Low sensitivity (shift in dose response curve)	Standard is degraded	Replace standard
Analyses of two dilutions of a biological sample do not agree (i.e., more than 20% difference)	Interfering substances are present	Purify sample prior to analysis by ELISA ¹⁰
Only Total Activity (TA) wells develop	Trace organic contaminants in the water source	Replace activated carbon filter or change source of UltraPure water

References

- 1. Stjernschantz, J. and Resul, B. Phenyl substituted prostaglandin analogs for glaucoma treatment. *Drugs of the Future* **17**, 691-704 (1992).
- Abramovitz, M., Adam, M., Boie, Y., et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 1483, 285-293 (2000).
- Camras, C.B., Alm, A., Watson, P., et al. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology 103, 1916-1924 (1996).
- 4. Goh, Y. and Kishino, J. Pharmacological characterization of prostaglandinrelated ocular hypotensive agents. *Jpn. J. Ophthamol.* **38**, 236-245 (1994).
- 5. Basu, S. and Sjöquist, B. Development of a radioimmunoassay for latanoprost and its application in a long-term study in monkeys. *Prostaglandins, Leukotrienes and Essential Fatty Acids* **55**, 427-432 (1996).
- Maclouf, J., Grassi, J., and Pradelles, P. Development of enzyme-immunoassay techniques for the measurement of eicosanoids, Chapter 5, in Prostaglandin and Lipid Metabolism in Radiation Injury. Walden, T.L., Jr. and Hughes, H.N., editors, Plenum Press, Rockville, 355-364 (1987).
- 7. Pradelles, P., Grassi, J. and Maclouf, J. Enzyme immunoassays of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay. *Anal. Chem.* **57**, 1170-1173 (1985).
- 8. Powell, W.S. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica, Chapter 58, *in* Methods in Enzymology. Academic Press, New York, 467-477 (1982).
- 9. Powell, W.S. Reversed-phase high-pressure liquid chromatography of arachidonic acid metabolites formed by cyclooxygenase and lipoxygenases. *Anal. Biochem.* **148**, 59-69 (1985).
- 10. Maxey, K.M., Maddipati, K.R. and Birkmeier, J. Interference in enzyme immunoassays. *J. Clin. Immunoassay* **15**,116-120 (1992).

NOTES

11 10 0 ∞ 9 2 4 3 2

Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

@10/06/2022, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.

